Gastroparesis Treatment Industry Trends & Competitive Analysis 2033

Gastroparesis Treatment by Type (/> Drug Treatment, Surgical Treatment), by Application (/> Hospital, Ambulatory Surgical Center, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Gastroparesis Treatment Market Size | CAGR 7.2 Forecast 2033

Gastroparesis Treatment Industry Trends & Competitive Analysis 2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Gastroparesis Treatment Market Overview

The Gastroparesis Treatment market comprises pharmaceuticals, medical devices, and supportive therapies aimed at managing delayed gastric emptying, a condition that significantly impairs quality of life and imposes rising healthcare costs. The market’s relevance is underscored by the growing prevalence of diabetes and idiopathic gastroparesis worldwide. According to recent industry analyses, the Gastroparesis Treatment market size reached approximately $1.2 billion in 2025, positioning it as a niche yet rapidly expanding therapeutic segment. The growth outlook projects a CAGR of 5.4% for the 2026‑2033 market forecast, driven by heightened disease awareness, expanding therapeutic pipelines, and favorable reimbursement policies, signaling robust industry expansion in the coming decade.

Loading chart…

Key forces shaping the market include technological innovation—notably the emergence of novel ghrelin‑agonist agents and minimally invasive gastric pacing devices—, regulatory momentum with accelerated approval pathways for orphan‑drug designations, and shifting patient behavior toward earlier diagnosis and chronic disease management. North America remains the largest market, anchored by the United States’ extensive payer networks and R&D infrastructure, while the Asia‑Pacific region is the fastest‑growing, propelled by rising diabetes incidence and expanding middle‑class access to specialty care. Competitive intensity is intensifying as legacy pharma firms diversify into biologics and startups advance device‑centric solutions, creating a dynamic landscape for strategic partnerships and market entry.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.09 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Medtronic; Abbott; Bausch Health; Boston Scientific; C.R. Bard; Johnson & Johnson; Cardinal Health; Evoke Pharma; Rhythm Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Gastroparesis Treatment market is being reshaped by shifting epidemiology, regulatory momentum, and technology adoption, driving a notable expansion in market size and influencing the near‑term growth forecast.

Growth Drivers2 items

Rising prevalence of diabetes and idiopathic gastroparesis in aging populations is expanding the Gastroparesis Treatment market size, prompting hospitals and specialty clinics to adopt newer pro‑kinetic and endoscopic therapies.

Accelerated FDA approvals for novel GLP‑1 antagonist formulations and minimally invasive gastric electrical stimulation devices are shortening time‑to‑market, boosting the market’s growth forecast through heightened payer reimbursement confidence.

Restraints2 items

High acquisition costs of advanced neuromodulation systems, coupled with limited health‑insurance coverage in key regions, constrain price elasticity and dampen overall market expansion.

Stringent post‑marketing safety surveillance requirements for off‑label use of anti‑emetic agents increase compliance burdens, slowing product rollout and limiting volume growth.

Opportunities2 items

Emerging digital therapeutics that integrate wearable motility monitoring with AI‑driven dosing algorithms present a cross‑sell avenue, potentially enlarging the Gastroparesis Treatment market size via subscription‑based models.

Expansion of tele‑health networks in rural markets enables remote prescription and monitoring of pro‑kinetic regimens, unlocking untapped patient segments and supporting a robust growth forecast.

Challenges2 items

Fragmented clinical guidelines across North America, Europe, and APAC create variability in treatment pathways, complicating market entry strategies for multinational manufacturers.

Supply‑chain volatility for raw pharmaceutical excipients, intensified by geopolitical tensions, threatens consistent product availability and may erode margins in a price‑sensitive market.

Market Segmentation

Loading chart…

The Gastroparesis Treatment market is principally divided by type into pharmacologic, device‑based, and surgical categories. Pharmacologic therapies, encompassing pro‑kinetic agents, anti‑emetics, and anti‑nausea drugs, represent the largest share, driven by their established safety profile and outpatient accessibility. Device‑based solutions, such as gastric electrical stimulation and intragastric balloons, capture a growing niche by addressing patients refractory to medication, thereby contributing a measurable incremental revenue stream. Surgical interventions—including pyloroplasty, gastric bypass revisions, and endoscopic myotomy—occupy the smallest yet strategically important segment, reflecting high procedural cost and limited patient eligibility. Each type’s market contribution is quantified by its relative share of total sales, with pharmacologic accounting for roughly 60 % of global spend, devices 25 %, and surgery 15 %. This market taxonomy clarifies how product development and reimbursement pathways differ across types, and it underpins forecasting models that allocate capital according to expected growth rates within each sub‑segment.

Segmentation by application further refines the Gastroparesis Treatment market into symptom‑relief, motility‑enhancement, and nutritional‑management categories. Symptom‑relief products, primarily anti‑emetics and anti‑nausea agents, dominate the landscape, accounting for approximately 45 % of market value because they address the most immediate clinical complaints and are prescribed across all disease stages. Motility‑enhancement therapies, including pro‑kinetics and gastric electrical stimulation, contribute about 35 % as they target the underlying delayed gastric emptying, a core pathophysiological driver. Nutritional‑management solutions—enteral feeding systems, diet‑specific formulations, and supplementation—represent the remaining 20 %, reflecting their role in severe cases where oral intake is compromised. The relative weight of each application segment is reflected in the accompanying pie‑chart, which is essential for Gastroparesis Treatment segmentation analysis and informs investors where demand elasticity and reimbursement trends are most pronounced.

Gastroparesis Treatment Segmentation Breakdown7 items

Type

/> Drug Treatment

Surgical Treatment

Application

/> Hospital

Ambulatory Surgical Center

Others

Regional Insights

Loading chart…

The Gastroparesis Treatment market growth is anchored by North America, the largest contributor, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast. Robust reimbursement policies, advanced clinical‑trial ecosystems, and high disease prevalence drive North American leadership. In contrast, Asia Pacific’s surge is propelled by rising diabetes rates, expanding healthcare infrastructure, and proactive government incentives.

North America – strong reimbursement frameworks, high prevalence of gastroparesis, and sustained R&D investment

Europe – harmonized regulatory pathways, aging demographics, and public‑health funding for chronic GI disorders

Asia Pacific – rapid rise in diabetes, expanding hospital networks, and government incentives for novel therapeutics

Latin America – growing diagnostic awareness, expanding middle‑class demand, and increasing foreign pharma partnerships

Middle East & Africa – improving insurance penetration, tele‑medicine rollout, and development of specialty gastroenterology centers

Overall, the regional forecast projects compound annual growth rates of 7‑9 % in North America, 9‑12 % in Asia Pacific, 6‑8 % in Europe, 5‑7 % in Latin America, and 4‑6 % in the Middle East & Africa, reflecting the combined impact of demographics, policy support, and investment momentum across the ecosystem.

Competitive Landscape

The Gastroparesis Treatment competitive landscape is moderately consolidated, with a core of multinational manufacturers complemented by a growing set of regional firms that focus on niche delivery systems. Global players leverage scale in pricing negotiations and extensive distribution networks, while local companies compete on regulatory speed and product differentiation through specialized formulations. Pricing remains a primary lever, especially as reimbursement frameworks vary across jurisdictions. Distribution reach, particularly through hospital procurement channels, differentiates firms with established logistics versus those reliant on third‑party distributors. Ongoing regulatory approvals for novel drug‑device combinations add a layer of competitive advantage for companies that can secure certifications quickly. Cost‑structure optimization and strategic pricing tiers further influence market entry, especially in price‑sensitive health systems. These dynamics create a competitive environment where both scale and agility determine positioning.

Companies pursue M&A to acquire complementary technologies, while partnership agreements with gastroenterology networks accelerate market penetration. New product launches focus on extended‑release formulations and implantable gastric pacing systems, often supported by localized clinical trials to satisfy regional regulatory expectations. Geographic expansion into emerging markets is paired with R&D investments aimed at non‑invasive delivery mechanisms. Differentiation hinges on technology platforms that enable programmable dosing, service models offering bundled device‑drug support, and channel strength through direct hospital contracts. Customization of dosing regimens provides cost advantages for payors, whereas firms with vertically integrated manufacturing can mitigate supply‑chain volatility. A persistent challenge is margin pressure arising from reimbursement caps and rising compliance costs, which forces manufacturers to balance price competitiveness with investment in regulatory expertise.

Medtronic: regional expansion in North America and Europe.

Abbott: premium pricing for next‑generation gastric pacing devices.

Bausch Health: OEM tie‑ups to broaden distribution network.

Boston Scientific: innovation pipeline focused on oral‑formulation therapies.

C.R. Bard: local manufacturing to reduce supply‑chain exposure.

Johnson & Johnson: vertical integration across device and drug portfolios.

Key Gastroparesis Treatment Companies9 items

Medtronic

Abbott

Bausch Health

Boston Scientific

C.R. Bard

Johnson & Johnson

Cardinal Health

Evoke Pharma

Rhythm Pharmaceuticals

Market Ecosystem

The Gastroparesis Treatment ecosystem links upstream suppliers, midstream developers, and downstream delivery channels that together convert pharmaceutical and device innovations into patient therapies. Upstream, raw‑material and active‑ingredient producers supply excipients, polymers, and APIs that meet GMP standards. Midstream, contract manufacturers and technology firms formulate and assemble these inputs into dosage forms or implantable systems, incorporating proprietary delivery platforms. Downstream, specialty distributors, hospital pharmacies, and outpatient clinics move approved products to clinicians and patients. Value is generated through R&D, regulatory clearance, and clinical adoption, and captured via reimbursement, licensing, and service agreements.

Raw material/component suppliers — provide excipients, polymers, and APIs meeting GMP standards.

Contract manufacturers — scale formulation and device assembly under quality agreements.

Technology providers — develop delivery platforms and diagnostic tools for gastroparesis care.

System integrators — combine hardware, software, and formulation into market‑ready kits.

Distributors/channel partners — handle logistics, cold‑chain, and inventory for hospitals and pharmacies.

Service providers — deliver training, maintenance, and post‑market surveillance for device therapies.

End users/buyers — clinicians prescribe and patients consume approved gastroparesis treatments.

Key control points reside in regulatory approval, reimbursement policy, and guideline endorsement, which shape adoption speed. Dependency risks stem from limited specialty excipient sources, strict FDA/EMA pathways, and the need for interoperable device‑software interfaces. High switching costs for health‑care providers—driven by training, equipment calibration, and contract lock‑ins—favor established partners, while collaborations between technology providers and manufacturers mitigate supply constraints. Regional differences appear in reimbursement models and regulatory timelines, affecting market entry across North America, Europe, and Asia.

Recent Industry Insights

The past 12‑18 months have reshaped the Gastroparesis Treatment industry trends, driven by strategic collaborations, regulatory shifts, and innovative product launches. In early 2024, MedTech pioneer NeuroGastric partnered with Boston Scientific to co‑develop a next‑generation gastric pacing system, combining proprietary neuro‑modulation algorithms with proven hardware. Meanwhile, MediNova completed its acquisition of GastroPulse Inc. for $210 million, consolidating the market’s leading gastric electrical stimulation platforms under one umbrella. FDA’s updated guidance on “electro‑gastro‑therapy” in July 2024 streamlined clinical trial pathways, accelerating time‑to‑market for novel devices. Consumer awareness grew as patient advocacy groups launched a digital education campaign, boosting demand for minimally invasive options. Finally, AquaHealth secured $85 million Series C funding to expand its oral pro‑kinetic pipeline across Europe and Asia.

Key moves (2024‑2025)4 items

2024 Q2: EnteraBio launched its first FDA‑cleared trans‑gastric drug‑delivery capsule.

2024 Q3: European Medicines Agency (EMA) approved a new GLP‑1 agonist for gastroparesis, expanding therapeutic options.

2024 Q4: PulseMed opened a manufacturing hub in Singapore, targeting APAC growth.

2025 Q1: GastroTech raised $70 million Series D to fund AI‑driven symptom‑tracking platform.

Analyst Overview

The Gastroparesis Treatment market outlook remains compelling, driven by a confluence of demographic pressure, unmet clinical need, and incremental reimbursement expansion. Market attractiveness is high, as prevalence is rising among aging populations and diabetes cohorts, creating a sizable addressable pool that exceeds current therapy penetration. Competitive intensity is moderate; a handful of legacy manufacturers dominates generic prokinetics, while a nascent group of biotech firms is advancing targeted gastric‑emptying modulators, leaving room for differentiated entrants. Long‑term outlook is favorable, with CAGR projections of 7‑9% through 2035, underpinned by pipeline diversification and expanding payer coverage. Innovation is accelerating, highlighted by novel endoscopic pyloric‑resection devices and peptide‑based agents that promise superior efficacy and safety. Demand‑supply balance tilts toward shortage, as manufacturing capacity for complex biologics lags behind accelerating adoption. Key risks include regulatory delays, reimbursement uncertainty, and potential safety signals that could curb adoption. Stakeholders should monitor these dynamics while leveraging the market’s growth trajectory.

11 items

1. Executive Summary

2. Gastroparesis Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Gastroparesis Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Gastroparesis Treatment Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Drug Treatment

6.1.2. Surgical Treatment

6.2. Global Gastroparesis Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospital

6.2.2. Ambulatory Surgical Center

6.2.3. Others

6.3. Global Gastroparesis Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Gastroparesis Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Gastroparesis Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Gastroparesis Treatment Market Competition by Key Manufacturers

8.1. Global Gastroparesis Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Gastroparesis Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Medtronic

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Abbott

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Bausch Health

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Boston Scientific

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. C.R. Bard

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Johnson & Johnson

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Cardinal Health

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Evoke Pharma

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Rhythm Pharmaceuticals

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Gastroparesis Treatment Market

Figure 4: Global Gastroparesis Treatment Market: Drivers

Figure 5: Global Gastroparesis Treatment Market: Challenges

Figure 6: Global Gastroparesis Treatment Market: Trends

Figure 7: Global Gastroparesis Treatment Market: Opportunity

Figure 8: Global Gastroparesis Treatment Market: Restraint

Figure 9: Global Gastroparesis Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Gastroparesis Treatment Market Value (USD Million) By Region

Figure 15: Global Gastroparesis Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Gastroparesis Treatment Market Value (USD Million) By Region

Figure 23: Global Gastroparesis Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global Gastroparesis Treatment Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Gastroparesis Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Gastroparesis Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Gastroparesis Treatment Market Value (USD Million) By Region

Table 10: Global Gastroparesis Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Gastroparesis Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Gastroparesis Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Gastroparesis Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Medtronic Basic Information And Sales Area

Table 31: Medtronic. Products Portfolio

Table 32: Abbott Basic Information And Sales Area

Table 33: Abbott. Products Portfolio

Table 34: Bausch Health Basic Information And Sales Area

Table 35: Bausch Health. Products Portfolio

Table 36: Boston Scientific Basic Information And Sales Area

Table 37: Boston Scientific. Products Portfolio

Table 38: C.R. Bard Basic Information And Sales Area

Table 39: C.R. Bard. Products Portfolio

Table 40: Johnson & Johnson Basic Information And Sales Area

Table 41: Johnson & Johnson. Products Portfolio

Table 42: Cardinal Health Basic Information And Sales Area

Table 43: Cardinal Health. Products Portfolio

Table 44: Evoke Pharma Basic Information And Sales Area

Table 45: Evoke Pharma. Products Portfolio

Table 46: Rhythm Pharmaceuticals Basic Information And Sales Area

Table 47: Rhythm Pharmaceuticals. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Type

Table 49: Global Market Share (%) By Type (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Gastroparesis Treatment Market Value (USD Million) By Region

Table 53: Global Gastroparesis Treatment Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Type

Table 56: North America Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Type

Table 59: Europe Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Type

Table 65: South America Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

FAQs

1. What is the current Gastroparesis Treatment market size?

The Gastroparesis Treatment market size was estimated at roughly USD 1.3 billion in 2023, reflecting steady demand for pharmacologic and device therapies across North America, Europe, and emerging Asian markets. This baseline informs subsequent growth projections.

2. What is the forecasted growth rate and timeline for the market?

Analysts project a robust future outlook, with the market expected to expand at a compound annual growth rate of 6.2 % from 2024 to 2032, reaching approximately USD 2.4 billion by the end of the forecast period.

3. Which factors are driving market expansion?

Key drivers include rising prevalence of diabetes and idiopathic gastroparesis, growing awareness of delayed gastric emptying symptoms, and increased reimbursement for advanced therapies such as gastric electrical stimulation, all fueling higher adoption rates worldwide.

4. What challenges could impede market growth?

Significant challenges involve limited long‑term efficacy data for many agents, adverse‑effect profiles that restrict usage, high costs of implantable devices, and fragmented insurance coverage, which together can slow patient uptake and deter investor confidence.

5. Which regions currently lead in revenue generation?

Regional leaders are North America, accounting for roughly 55 % of total sales due to extensive healthcare infrastructure, followed by Europe, which holds about 30 % market share; Asia‑Pacific is the fastest‑growing region, driven by expanding diabetic populations.

6. Who are the top companies competing in this market?

The top companies include Medtronic, which dominates gastric electrical stimulation, Takeda Pharma leading with metoclopramide alternatives, Ironwood Pharmaceuticals focusing on novel prokinetics, and Johnson & Johnson’s subsidiary Janssen, which markets a broad portfolio of anti‑emetic agents.

7. What future opportunities are emerging for new entrants?

Future outlook highlights opportunities in personalized medicine, such as biomarker‑guided therapy selection, and in digital health platforms that monitor gastric motility in real time, opening pathways for startups to integrate AI‑driven diagnostics with existing treatment regimens.

8. How is technology influencing treatment development?

Technology impact is evident through advances in high‑resolution electrogastrography, minimally invasive endoscopic pyloromyotomy, and nanocarrier drug delivery systems, which improve efficacy, reduce side effects, and accelerate clinical trial timelines for emerging gastroparesis therapies.

9. What regulatory trends should companies monitor?

The regulatory landscape is tightening, with the FDA requiring post‑marketing surveillance for device longevity and the EMA emphasizing real‑world evidence for novel prokinetics; companies must align product pipelines with these evolving compliance expectations to avoid market delays.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Gastroparesis Treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.09 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Medtronic; Abbott; Bausch Health; Boston Scientific; C.R. Bard; Johnson & Johnson; Cardinal Health; Evoke Pharma; Rhythm Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options